Diabetes mellitus and atrial remodeling: mechanisms and potential upstream therapies (Q38234313)

31 August 2017

Diabetes mellitus and atrial remodeling: mechanisms and potential upstream therapies (English)

1 reference

31 August 2017

1 reference

Qitong Zhang

1

1 reference

31 August 2017

Tong Liu

series ordinal

2

1 reference

31 August 2017

Chee Y Ng

series ordinal

3

1 reference

31 August 2017

Guangping Li

series ordinal

4

1 reference

31 August 2017

1 October 2014

1 reference

Cardiovascular Therapeutics

31 August 2017

1 reference

31 August 2017

32

1 reference

31 August 2017

233-241

1 reference

31 August 2017

5

1 reference

'Lone' atrial fibrillation: hunting for the underlying causes and links

31 August 2017

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Effect of obesity on p-wave parameters in a Chinese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Atrial fibrillation in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Diabetes mellitus, glycemic control, and risk of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Type 2 diabetes mellitus and risk of incident atrial fibrillation in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Oxidative stress markers are associated with persistent atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

The biochemistry of the complications of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Platelet functions in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Receptor for advanced glycation end products (RAGE) in vascular and inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Receptor for advanced glycation end products (RAGE): novel biomarker and therapeutic target for atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Atrial conduction time and atrial mechanical function in patients with impaired fasting glucose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Assessment of atrial electromechanical delay, diastolic functions, and left atrial mechanical functions in patients with type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Intra- and interatrial conduction delay: implications for cardiac pacing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Impaired atrial electromechanical function and atrial fibrillation promotion in alloxan-induced diabetic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Recent insights into the role of the autonomic nervous system in the creation of substrate for atrial fibrillation: implications for therapies targeting the atrial autonomic nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Alteration in haemodynamics and pathological changes in the cardiovascular system during the development of Type 2 diabetes mellitus in OLETF rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Impairment of baroreflex control of heart rate and structural changes of cardiac ganglia in conscious streptozotocin (STZ)-induced diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Parasympathetic dysfunction is associated with baroreflex and chemoreflex impairment in streptozotocin-induced diabetes in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Loss of cardiac sympathetic neurotransmitters in heart failure and NE infusion is associated with reduced NGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Acetylcholine release in human heart atrium: influence of muscarinic autoreceptors, diabetes, and age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Remodeling of cardiac cholinergic innervation and control of heart rate in mice with streptozotocin-induced diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Mechanism of and therapeutic strategy for atrial fibrillation associated with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Thiazolidinediones and PPARγ agonists: time for a reassessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Probucol and succinobucol in atrial fibrillation: pros and cons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Probucol attenuates atrial structural remodeling in prolonged pacing-induced atrial fibrillation in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Single oral dose of geranylgeranylacetone induces heat-shock protein 72 and renders protection against ischemia/reperfusion injury in rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Angiotensin II type 1 receptor blocker attenuates diabetes-induced atrial structural remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Advanced glycation end-product-induced mitogenesis and collagen production are dependent on angiotensin II and connective tissue growth factor in NRK-49F cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Statins and prevention of atrial fibrillation in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Prevention of atrial fibrillation with omega-3 fatty acids: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Reactive oxygen species-targeted therapeutic interventions for atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

Diastolic Stiffness of the Failing Diabetic Heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12089

21 January 2018

Identifiers

DOI

10.1111/1755-5922.12089

1 reference

31 August 2017

1 reference